Olivier Mueller

Showing 1-14 of 14 articles

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial

Iglesias JF, Mueller O, Zaugg S, Roffi M, Kurz D, Vuilliomenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T

August 24, 2018 | 10.4244/EIJ-D-17-00734

Interventions for valvular disease

Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses

Seiffert M, Treede H, Schofer J, Linke A, Wöhrle J, Baumbach H, Mehilli J, Bapat V, Simonato M, Walther T, Kullmer M, Boekstegers P, Ensminger S, Kurz T, Eltchaninoff H, Rastan A, Werner N, de Weger A, Frerker C, Lauer B, Mueller O, Whisenant B, Thukkani A, Weisz G, Dvir D

July 20, 2018 | 10.4244/EIJ-D-17-00546

Interventions for valvular disease

How should I treat an Edwards SAPIEN 3 aortic valve embolisation during a transaortic transcatheter aortic valve implantation?

Fournier S, Monney P, Roguelov C, Ferrari E, Eeckhout E, Mueller O, Durko A, Van Mieghem N, Kappetein A, Margey R

July 20, 2017 | 10.4244/EIJ-D-16-00592

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Mueller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Coronary interventions

Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial

Franzone A, Taniwaki M, Rigamonti F, Heg D, Piccolo R, Roffi M, Tüller D, Mueller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T

August 5, 2016 | 10.4244/EIJV12I5A99

Coronary interventions

How should I treat a coronary artery fistula complicated with myocarditis – PCI or surgery?

Morawiec B, Mueller O, Khatchatourov G, Goy J-J, Qureshi S, Silaschi M, Wendler O

June 10, 2016 | 10.4244/EIJV12I2A45

Tools & Techniques: The year of the textbook – time to say good-bye!

Naber C, Sachdev B, Mueller O, Eeckhout E, Fajadet J

May 15, 2012 | 10.4244/EIJV8I1A24

AsiaPCR/SingLive: in its third year and growing

Lim E, Lim C, Mueller O, Yeo KK, Lim S-T, Koh T-H, Eeckhout E

February 21, 2012 | 10.4244/EIJV7I10A184

Complications with a happy ending

Mueller O, Lerman A, Eeckhout E

December 30, 2011 | 10.4244/EIJV7I8A141

Clinical outcomes after PCI for acute coronary syndrome in unprotected left main coronary artery disease: insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study

Puricel S, Adorjan P, Oberhänsli M, Stauffer J-C, Moschovitis A, Vogel R, Goy J-J, Mueller O, Eeckhout E, Togni M, Wenaweser P, Meier B, Windecker S, Cook S

October 28, 2011 | 10.4244/EIJV7I6A112

Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction

Mueller O, Delrue L, Hamilos M, Vercauteren S, Ntalianis A, Trana C, Mangiacapra F, Dierickx K, De Bruyne B, Wijns W, Behfar A, Barbato E, Terzic A, Vanderheyden M, Bartunek J

August 30, 2011 | 10.4244/EIJV7I4A75

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

Cuisset T, Valgimigli M, Mudra H, Mueller O, Wijns W, Huber K

May 25, 2010

Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Mueller O, Windecker S, Cuisset T, Fajadet J, Mason M, Zuffi A, Doganov A, Eeckhout E

August 20, 2008

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Cuisset T, Mudra H, Mueller O, Vogt P, Angelillo-Scherrer A, Huber K

August 20, 2008

Latest news

NEW ISSUE

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

AHEAD OF PRINT

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

AHEAD OF PRINT

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

AHEAD OF PRINT

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.